Healio: HCV triple therapy post-liver transplant yields moderate response, significant adverse events

HCV triple therapy post-liver transplant yields moderate response, significant adverse events
June 27, 2013

Liver transplant recipients with hepatitis C experienced moderate early response rates but frequent side effects from triple therapy with antivirals in a recent study.

Researchers evaluated 60 liver transplant recipients with recurrent HCV genotype 1 and significant fibrosis who underwent treatment with pegylated interferon alfa-2a and ribavirin (PEG/RBV) and either telaprevir (TVR) (n=35) or boceprevir (BOC) (n=25), with a minimum follow-up of 12 weeks (mean follow-up, 35 weeks).
Full Story » 

USPSTF recommends HCV testing for high-risk adults, baby boomers June 26, 2013
The United States Preventive Services Task Force recently recommended screening for adults at high risk for hepatitis C virus infection and one-time screening for all Americans born between 1945 and 1965 because the birth cohort is at greater risk for infection compared with other age groups.
Full Story

 Meta-analysis linked NAFLD, vitamin D deficiency
June 26, 2013
Researchers performed a systematic review of 17 case-control and cross-sectional studies, assessing the association between nonalcoholic fatty liver disease (NAFLD) and serum levels of 25-hydroxy vitamin D (25[OH]D). Included studies were selected from PubMed and EMBASE databases and published before April 22, 2013, evaluated vitamin D levels among cases and controls, and were based in North America (six studies), Asia (four studies) and Europe or Israel (seven studies).
Full Story...